Attached files
| file | filename |
|---|---|
| EX-10.17 - EX-10.17 - FATE THERAPEUTICS INC | fate-ex1017_612.htm |
| EX-31.1 - EX-31.1 - FATE THERAPEUTICS INC | fate-ex311_12.htm |
| EX-10.16 - EX-10.16 - FATE THERAPEUTICS INC | fate-ex1016_611.htm |
| EX-10.5 - EX-10.5 - FATE THERAPEUTICS INC | fate-ex105_609.htm |
| EX-10.15 - EX-10.15 - FATE THERAPEUTICS INC | fate-ex1015_610.htm |
| EX-32.1 - EX-32.1 - FATE THERAPEUTICS INC | fate-ex321_8.htm |
| 10-K - 10-K - FATE THERAPEUTICS INC | fate-10k_20151231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements
|
|
1. |
Registration Statement (Form S‑3 No. 333‑199107) of Fate Therapeutics, Inc., and |
|
|
2. |
Registration Statements (Form S‑8 Nos. 333‑191576, 333‑194625, 333-202690, and 333-209392) pertaining to the 2007 Equity Incentive Plan, the 2013 Stock Option and Incentive Plan, and 2013 Employee Stock Purchase Plan of Fate Therapeutics, Inc.; |
of our report dated March 3, 2016, with respect to the consolidated financial statements of Fate Therapeutics, Inc. included in this Annual Report (Form 10‑K) of Fate Therapeutics, Inc. for the year ended December 31, 2015.
/s/ Ernst & Young LLP
San Diego, California
March 3, 2016